AMOLYT PHARMA
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
AMOLYT PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Wellness
Founded:
2015-01-01
Address:
Écully, Rhone-Alpes, France
Country:
France
Website Url:
http://www.amolytpharma.com
Total Employee:
11+
Status:
Active
Contact:
33 428 01 21 54
Email Addresses:
[email protected]
Total Funding:
311.28 M USD
Technology used in webpage:
Bunny Fonts Constant Hosting
Similar Organizations
Cimeio Therapeutics
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series C - Amolyt Pharma
Tekla Capital Management
Tekla Capital Management investment in Series C - Amolyt Pharma
Sofinnova Partners
Sofinnova Partners investment in Series C - Amolyt Pharma
Credit Agricole Entreprises
Credit Agricole Entreprises investment in Series C - Amolyt Pharma
Pontifax
Pontifax investment in Series C - Amolyt Pharma
Intermediate Capital Group
Intermediate Capital Group investment in Series C - Amolyt Pharma
Bpifrance
Bpifrance investment in Series C - Amolyt Pharma
Sectoral Asset Management
Sectoral Asset Management investment in Series C - Amolyt Pharma
CTI Life Sciences Fund
CTI Life Sciences Fund investment in Series C - Amolyt Pharma
Kurma Partners
Kurma Partners investment in Series C - Amolyt Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-29 | Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.amolytpharma.com Semrush global rank: 8.39 M Semrush visits lastest month: 539
Unable to get host informations!!!
More informations about "Amolyt Pharma"
Amolyt Pharma Enters into Definitive Agreement to be Acquired …
Disease, an organization with proven expertise and a successful track-record in bringing innovative therapies to patients with rare diseases globally.” Pierre Legault, hairman of Amolyt …See details»
Acquisition of Amolyt Pharma completed - AstraZeneca
Jul 15, 2024 AstraZeneca today announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel …See details»
AstraZeneca Closes Acquisition of Amolyt Pharma
AstraZeneca Closes Acquisition of Amolyt Pharma Lyon, France, and Cambridge, MA, July 15, 2024 — Amolyt Pharma, a global, clinical-stageSee details»
Amolyt Pharma - Crunchbase Company Profile & Funding
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential …See details»
Amolyt Pharma - LinkedIn
Amolyt Pharma | 9,044 followers on LinkedIn. Advancing peptides for the treatment of rare endocrine and related diseases | Amolyt Pharma is building on its team’s established expertise …See details»
Amolyt Pharma conclut un accord définitif visant son acquisition …
Amolyt Pharma conclut un accord définitif visant son acquisition par AstraZeneca • AstraZeneca fera l’acquisition d’Amolyt Pharma pour un total pouvant atteindre 1,05 milliard de dollars. • …See details»
Amolyt Pharma - Ownership and Business Overview - Mergr
Mar 14, 2024 www.amolytpharma.com. Profile Investors (3) Analytics Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing …See details»
Amolyt Pharma - workinbiotech.com
Amolyt Pharma, a clinical stage, global biotech company founded in 2014, is developing innovative therapeutic strategies for patients who suffer from rare endocrine and metabolic …See details»
Amolyt Pharma - LinkedIn
Amolyt Pharma | 9 082 abonnés sur LinkedIn. Advancing peptides for the treatment of rare endocrine and related diseases | Amolyt Pharma is building on its team’s established expertise …See details»
Amolyt Pharma SAS - Drug pipelines, Patents, Clinical trials
Nov 1, 2024 amolytpharma.com. Startups | Subsidiary Company | 2015 | France | 10-50 | amolytpharma.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Amolyt Pharma - Company Profile & Staff Directory | ContactOut
Amolyt Pharma is building on its team’s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and …See details»
Amolyt Pharma - EQT Group
Dec 13, 2024 Amolyt Pharma is a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseasesSee details»
About Amolyt Pharma - pharmiweb.jobs
Mar 14, 2024 Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare …See details»
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, …
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and MetabolicSee details»
Amolyt Pharma Company Profile 2024: Valuation, Investors
Amolyt Pharma General Information Description. Operator of a clinical-stage biotechnology company intended for the treatment of endocrine and metabolic disorders. The company offers …See details»
Amolyt Pharma - Craft
Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic …See details»
Amolyt Pharma Company Overview, Contact Details
Jan 6, 2023 amolytpharma.com. SIC Code 8733 - Noncommercial Research Organizations. NAICS Code 541714 - Research and Development in Biotechnology (except …See details»
Amolyt Pharma - Overview, News & Similar companies - ZoomInfo
May 31, 2022 Amolyt Pharma contact info: Phone number: +33 472189428 Website: www.amolytpharma.com What does Amolyt Pharma do? Founded in 2014, Amolyt Pharma is …See details»
Amolyt Pharma Appoints Pierre Legault as a Director and …
Jun 8, 2020 LYON, France, and NEWTON, MA, June 8, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine …See details»
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief …
1 day ago CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as …See details»